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Abstract
The IPC1 gene from Saccharomyces cerevisiae, which encodes inositolphosphorylceramide (IPC) synthase, was first
identified as a novel and essential gene encoding resistance to the natural product antifungal aureobasidin A (AUR1). The
formation of IPC in fungi is essential for viability, suggesting inhibitors of IPC1p function would make ideal antifungal drug
candidates. Homologs of the AUR1/IPC1 gene were identified from a number of human pathogenic fungi, Candida glabrata,
Candida krusei, Candida parapsilosis, Candida tropicalis and Cryptococcus neoformans. Comparison of these genes with other
homologous genes from Candida albicans, Aspergillus fumigatus, Aspergillus nidulans, Saccharomyces cerevisiae and
Schizosaccharomyces pombe reveals a conserved structural motif for inositolphosphoryl transferases which is similar to a
motif recently described for lipid phosphatases, but with unique characteristics. ß 2000 Published by Elsevier Science B.V.
All rights reserved.
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The number of patients with fungal infections has
been rising in recent years. The incidence of serious
fungal infections has risen because of increased num-
bers of immune suppressed patients, either by infec-
tion with HIV, intense chemotherapy for treatment
of cancer or organ transplantation [1,2]. Aspergillus
infections are now a major direct or contributing
cause of death in leukemia treatment centers, bone
marrow transplantation and solid tumor transplanta-
tion centers [3]. Aspergillus infections are currently
treated with amphotericin B or intaconazole, with a
34% clinical success rate. Non-albicans Candida in-
fections are also becoming more prevalent. These
Candida species are less susceptible to azoles and
are responsible for an increasing number of infec-
tions [4]. Infections with Candida krusei do not re-
spond to treatment with £uconazole, because the
strain is inherently resistant [5]. Azole resistant clin-
ical isolates of Candida albicans have also been seen.
The mode of resistance is either, molecular alteration
of the ERG11 gene, alteration of other genes in the
ergosterol pathway or increased expression of e¥ux
pumps [6]. Recently, a patient was described who
failed all antifungal therapy due to a Candida albi-
cans infection [7]. These types of infections, their in-
creasing incidence and resistance to azole antifungal
agents demonstrate the need for better antifungal
compounds with improved clinical success rates.
One potential antifungal target is sphingolipid bio-
synthesis. Sphingolipids are found in eukaryotic
membranes, containing a hydrophobic segment (ce-
ramide) which is a long chain base (LCB), sphingo-
sine in mammals, phytosphingosine (PHS) in fungi,
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yeast and plants, that is N-acylated with a very long
chain K-hydroxy fatty acid and linked to various
polar head groups. The biosynthesis of ceramide is
similar in all eukaryotes. The addition of the polar
head group to ceramide is a branch point in the syn-
thesis of sphingolipids between mammals and fungi.
In fungi, the head group is phosphoinositol linked by
a phosphodiester bond to the C1-hydroxyl of phyto-
ceramide to form inositolphosphoryl ceramide (IPC).
The antifungal compound aureobasidin A (AbA)
was isolated from Aureobasidium pulluans R106 and
is a cyclic depsipeptide (1100 Da) containing 8 amino
acids and a hydroxy acid [8]. AbA is a broad spec-
trum antifungal antibiotic with strong activity
against many pathogenic fungi, including Candida
ssp., Cryptococcus neoformans and some Aspergillus
ssp. [8,9]. The molecular target of the antifungal
AbA was identi¢ed as AUR1 in Saccharomyces cer-
evisiae, which was shown to be an essential gene
[10,11]. Homologs to the AUR1 gene were not ob-
served in a search of nucleic acid and protein data
bases. The AUR1 gene was therefore both novel and
essential. Subsequently, through a genetic approach,
the AUR1 gene was found to be required for the
formation of IPC in yeast, suggesting that the
AUR1 gene encodes part or all of IPC synthase,
the key enzyme in fungal sphingolipid biosynthesis
[12]. Biochemical support for the function of the
AUR1 gene as encoding IPC synthase activity was
demonstrated by the inhibition of IPC formation
by the antifungal antibiotic AbA [12]. Therefore,
the AUR1 gene is also called IPC1. Within the last
2 years, two additional antifungal agents that inhibit
IPC synthase have been described, khafrefungin and
rustmicin [13,14].
To understand the structure and function of IPC
synthase, genes from the fungal pathogens Candida
glabrata, Candida krusei, Candida parapsilosis, Can-
dida tropicalis and Cryptococcus neoformans were
cloned and sequenced. The sequences were compared
with the previously isolated AUR1/IPC1 genes and
also with another member of the inositol phosphoryl
transferase family, IPT1 [15].
Genomic DNA mini-libraries were prepared from
DNA isolated from Candida glabrata TF-17, Candida
krusei CK-4, Candida parapsilosis CP-11, Candida
tropicalis CT-18 and Cryptococcus neoformans
M1106. The sequence of primer pairs for PCR
were generated by aligning conserved regions of
known AUR1/IPC1 genes from S. cerevisiae, S.
pombe and C. albicans and synthesizing degenerate
primers (Table 1). Using touchdown PCR with ge-
nomic DNA as template and primer pairs IPCS-F1
or IPCS-F2 and IPCS-R2, the expected product of
456 bp was observed for the Candida species [16].
The ampli¢cation products were extracted and li-
Table 1
Degenerate primer pairs used for ampli¢cation of AUR1/IPC1 genes
aCodon symbols: R = A+G, Y = C+T, S = G+C, W = A+T, H = A+T+C, B = G+T+C, I = inosine.
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gated into pCR-Script and plasmid isolated after am-
pli¢cation in Escherichia XL1-Blue MRFP (Strata-
gene). Sequence analysis of these products con¢rmed
their identity as the expected middle third of the
coding region for AUR1/IPC1 homologs (data not
shown). Ampli¢cation of the AUR1/IPC1 homolog
of C. neoformans using the above primers failed to
give the correct product.
Genomic DNA was digested with several restric-
tion enzymes, electrophoresed and transfered to
Zeta-Probe GT (Bio-Rad). The PCR ampli¢cation
products corresponding to AUR1/IPC1 genes from
Candida species were used as probes of genomic
DNA isolated from the same species. Using this in-
formation, size fractionated genomic libraries were
constructed. The genomic DNA fragments were li-
gated into pBC, transformed into E. coli DH5K cells,
plated on large selective plates at approximately
1000 colonies per plate and grown overnight at
37‡C. Colony lifts were made using Colony/Plaque
Screen ¢lters (NEN Research Products) according to
manufacturer’s instructions. The ¢lters were prehy-
bridized and hybridized in a 50% formamide hybrid-
ization solution (50% formamide, 5USSPE, 1% SDS,
0.2UDenhardts, 50 Wg/ml sheared salmon sperm
DNA) at 45‡C. Filters were subsequently washed
twice in 2USSC, 0.1% SDS, followed by two washes
in 0.1USSC, 0.1% SDS at hybridization temperature
and exposed to Biomax MR2 X-ray ¢lm (Kodak),
overnight at 370‡C. Colonies with positive hybrid-
ization signals were picked, streaked on selective
plates for single colonies and allowed to grow over-
night at 37‡C. Colony lifts were made from these
isolates and hybridized, as above, until a single col-
ony was obtained which gave a uniformly positive
hybridization signal. Plasmid DNA was isolated
from positive clones, sequenced and overlapping
clones assembled into a single sequence. The nucleic
acid sequences have been deposited in GenBank (C.
glabrata BankIt251706 AF126176; C. krusei Bank-
It251729 AF126177; C. parapsilosis BankIt251731
AF126178; C. tropicalis BankIt251733 AF126179).
The predicted translation of the DNA sequences
from C. glabrata, C. krusei, C. parapsilosis and C.
tropicalis were aligned and are shown in Fig. 1.
The failure of the original primer pairs to amplify
the correct sequence from C. neoformans prompted
construction of a second set of degenerate primer
Fig. 1. Alignment of the IPC synthase proteins. The amino acid
sequence is from Candida glabrata (Cg IPC1), Candida krusei
(Ck IPC1), Candida parapsilosis (Cp IPC1), Candida tropicalis
(Ct IPC1). Lines over the sequence represent the regions used
for construction of DIPC-1F (forward primer) and DIPC-1R
(reverse primer) for ampli¢cation of C. neoformans AUR1/IPC1
gene.
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Fig. 2. Alignment of AUR1/IPC1 and IPT1 proteins. The area of high homology is shown. Ca IPT1, from Candida albicans gene se-
quence web site (http://alces.med.umn.edu/bin/genelist?genes), Sc IPT1, Af IPC1, An IPC1, Ca IPC1, Cg IPC1, Ck IPC1, Cp IPC1,
Ct IPC1, Sc IPC1 and Sp IPC1. Identical amino acids are highlighted in gray and are written below alignment. Symbols for motifs
are n, small neutral amino acid; P, aromatic amino acid; h, hydrophobic amino acid; b, branched amino acid; x, any amino acid.
Underlined sequences are domains 2 and 3 of the lipid phosphatase domains at 70% amino acid conservation [20].
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pairs based upon the alignment of the sequences
from the Candida species. These new primer-pairs,
DIPC-1F and DIPC-1R (Table 1), were used to am-
plify the conserved middle region of the C. neofor-
mans AUR1/IPC1 gene from genomic DNA. Ge-
nomic clones of the AUR1/IPC1 gene from C.
neoformans were identi¢ed and cloned as described
above for the Candida genes. A candidate clone for
the entire C. neoformans AUR1/IPC1 gene was ob-
tained as a 3.4-kb SalI fragment. Analysis of the
nucleic acid sequence of the C. neoformans AUR1/
IPC1 gene revealed a single 52-bp intron containing
splice junctions that conform to splice sites observed
in other C. neoformans intron containing genes [17].
The nucleic acid sequence for the C. neoformans
AUR1/IPC1 gene was deposited in GenBank (C. neo-
formans BankIt251743 AF126180). The predicted
translation product is 465 amino acids.
The predicted amino acid sequence of all the
AUR1/IPC1 genes were compared (Fig. 2). The ami-
no terminal 70^100 amino acids and the carboxyl
terminal 90^150 amino acids have little homology.
The central 250 amino acids, however, show a high
degree of homology, being 53^73% identical at the
nucleic acid level and 56^94% similar at the amino
acid level. The high degree of structural conservation
in this region of the AUR1/IPC1 genes suggests func-
tional conservation.
IPC synthase acts as an inositol phosphoryl trans-
ferase, catalyzing the transfer of the phosphoinositol
head group of phosphatidylinositol to the C1-hy-
droxyl of ceramide. Another inositol phosphoryl
transferase gene, IPT1, has been identi¢ed. The
IPT1 protein is reported to transfer the phosphoino-
sitol head group of phosphatidylinositol to manno-
syl-inositolphospho ceramide (MIPC) to form the
mannosyl-di(phosphoinositol) ceramide (M(IP)2C),
the most abundant sphingolipid in S. cerevisiae
[15]. Comparison of the IPT1 sequence from S. cer-
evisiae and a partial sequence from C. albicans re-
vealed identical motifs to the AUR1/IPC1 proteins
(Fig. 2). Analysis of the sequences of the AUR1/
IPC1 and IPT1 proteins revealed four conserved
domains, two of which are similar to the second
and third domains of the lipid phosphatase fam-
ily, nxPSGHn-x31ÿ54-SRxxxxxHxxxD [18,19]. Two
unique domains are noted in the AUR1/IPC1 and
IPT1 sequence comparisons. These domains
DhhnWxxYxxxHxxxP-(x54ÿ57)-YxxxGxxxGLxRxD-
x18, by secondary structure prediction, appear to be
in turn or coiled conformations between elements of
predicted L-sheet. Both conserved domains are pre-
dicted by hydropathy analysis to be neutral to hydro-
philic, indicating possible surface environments. This
is similar to the ¢rst conserved domain of lipid phos-
phatases (KXXhXXXRP) which by hydropathy
analysis is in a hydrophilic turn bordered by two
hydrophobic structural elements, in the case of lipid
phosphatases, predicted K-helices [20]. The high level
of conservation in domains one and two of the
inositol phosphoryl transferases implies that these
regions may be structurally important for transferase
activity. In addition, the sites of mutation to resist-
ance to aureobasidin A in two independent resistant
clones appear in the ¢rst of these conserved domains
[10,11].
The third domain of the AUR1/IPC1 proteins,
FGAxPLSHn, has 3 of 4 amino acids identical to
the second domain of the lipid phosphatase motifs,
substituting a leucine for a glycine residue and bor-
dered by small neutral amino acids. The fourth ino-
sitol phosphoryl transferase domain is YxxxxxxnT-
MYLxHHYxxDbxxGxxxn. Comparisons of the lipid
phosphatase third domain have been made for a lim-
ited set of inositol phosphoryl transferases [15,21].
With the greater number of sequences presented
herein, the homology to the third domain of the lipid
phosphatases is still evident, especially for the puta-
tive catalytic histidine and aspartate residues for the
inositol phosphoryl transferases. In addition, the
spacing between domains 3 and 4 in the inositol
phosphoryl transferases, except for the Sc ITP1p, is
consistent with the spacing properties of domains
2 and 3 of the lipid phosphatases.
From a mechanistic perspective, the hydrolysis of
phosphatidic acid by lipid phosphatases is believed to
proceed by nucleophilic attack of the imidazole ni-
trogen on the phosphate residue with subsequent re-
lease of the diacylglycerol (DAG), forming an inter-
mediate phospho-histidyl residue. This nucleophilic
attack is promoted by electron transfer to the imida-
zole of the histidine in the third motif by the adjacent
and conserved aspartate residue. The histidine in
the PSGH motif donates a proton to the DAG.
The phospho-histidyl residue is then hydrolyzed by
a water molecule, with increased nucleophilicity
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through hydrogen bonding to the histidine in the
PSGH motif [19].
The catalytic mechanism of lipid phosphatases
suggests a possible mechanism for the inositol phos-
phoryl transferases. In this hypothesis, the catalytic
triad, described for the lipid phosphatases, might act
in similar fashion in the inositol phosphoryl trans-
ferase family. The inositolphosphate from phospha-
tidylinositol potentially forms an intermediate with
the histidine residue in the fourth domain, to give a
unique inositol phosphoryl histidine intermediate.
This intermediate would then undergo hydrolysis
by attack of the C1-hydroxyl of ceramide, by in-
creased nucleophilicity through hydrogen bonding
with the third domain histidine and protected from
hydrolysis through the increased hydrophobicity of
the catalytic site. The inositolphosphate is transferred
to the C1 of ceramide. The role of the ¢rst two do-
mains of the inositol phosphoryl transferase family
might be to bind and stabilize the ceramide for posi-
tioning the C1-hydroxyl into the catalytic environ-
ment at the surface of the membrane where the
transfer takes place. This hypothesis provides a
framework for further studies by site-directed muta-
genesis and for understanding the inhibition of this
class of enzymes by previously identi¢ed inhibitors,
such as aureobasidin A.
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